Login to Your Account

Other News To Note

Tuesday, September 13, 2011
Oncothyreon Inc., of Seattle, licensed the preclinical Bcl-2 inhibitor sabutoclax from the Sanford-Burnham Medical Research Institute. Terms were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription